Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

INTEGRATE The Integrate study : An adaptive platform trial for the development of a new intervention to combat Lassa fever in Africa

Coordinator
Universite De Bordeaux, France
Runs
1 July 2023 to 30 June 2028
Status
Running
EU funding
€8.0m
Total cost
€8.8m
Partners
15 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101103204

What the project is doing

In the project's own words, from its summary on CORDIS.

Lassa fever (LF) is an acute febrile illness associated with bleeding, organ failure, and shock caused by Lassa virus. LF causes outbreaks in West African with in-hospital mortality up to 12%. Challenges in the clinical care of patients are multiple due to the limited availability of LF molecular diagnostics, the risk for nosocomial transmission, and the limited treatment options. There are currently no safe and effective treatment options available for LF, except ribavirin, the efficacy of which is debated.

The clinical development and accessibility of effective treatment options would be a game-changer towards reducing mortality associated with this disease and limiting its socio-economic impact. Nigeria is the country by far most affected by LF in the world with about 80% of global cases. The INTEGRATE consortium builds on a more than 15 years lasting highly successful collaboration between leading European and West African institutions focusing on the joint priority to better understand, manage, and combat LF in West Africa.

The overall objective of the INTEGRATE project is to establish a GCP-compliant adaptive clinical platform trial in West Africa (Nigeria and other countries) to test the efficacy, tolerability and safety of repurposed and novel drug candidates for the treatment of LF. To address this objective, we focus our activities on 3 specific objectives:- to develop and implement an adaptive randomised controlled phase II-III clinical platform trial evaluating drugs with proven preclinical activity against LF.- to build capacity for sustainable and independently conducted clinical research in West Africa by developing site, laboratory and medical care capacity through North-South and South-South technology transfer and training.

This activity encompasses capacity building of the lead Nigerian institution in GCP compliant clinical trial sponsorship.- to engage communities with the proposed work plan and to assess acceptability of the trial.

Topics

Who is involved

OrganisationCityCountryRole
Universite De BordeauxBordeauxFranceCoordinator
Médecins sans Frontières BelgiumBruxelles / BrusselBelgiumAssociatedpartner
Fondation Pour La Recherche Scientifique (fors)CotonouBJAssociatedpartner
Association Pac-CiAbidjanCIParticipant
Bernhard-Nocht-Institut Fuer TropenmedizinHamburgGermanyParticipant
University of HamburgHamburgGermanyParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
The Alliance for International Medical ActionParisFranceParticipant
Centre de Recherches Medicales de LambarénéLambarénéGAParticipant
Hopital National DonkaConakryGNAssociatedpartner
Phebe Hospital and School of NursingMonroviaLRAssociatedpartner
Alex Ekwueme Federal University Teaching Hospital AbakalikiAbakalikiNGAssociatedpartner
Federal Medical Centre OwoOwoNGParticipant
Irrua Specialist Teaching Hospital Board of ManagementIrruaNGParticipant
The University of North Carolina at Chapel HillChapel HillUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI